BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 20216424)

  • 1. Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone.
    Canuso CM; Grinspan A; Kalali A; Damaraju CV; Merriman U; Alphs L; Awad AG
    Int Clin Psychopharmacol; 2010 May; 25(3):155-64. PubMed ID: 20216424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia.
    Canuso CM; Bossie CA; Amatniek J; Turkoz I; Pandina G; Cornblatt B
    Early Interv Psychiatry; 2010 Feb; 4(1):64-78. PubMed ID: 20199482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone.
    Canuso CM; Youssef EA; Bossie CA; Turkoz I; Schreiner A; Simpson GM
    Int Clin Psychopharmacol; 2008 Jul; 23(4):209-15. PubMed ID: 18545059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
    Fowler JA; Bettinger TL; Argo TR
    Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H; Rui Q; Ning X; Xu H; Gu N
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
    Tzimos A; Samokhvalov V; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
    Am J Geriatr Psychiatry; 2008 Jan; 16(1):31-43. PubMed ID: 18165460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia.
    Luthringer R; Staner L; Noel N; Muzet M; Gassmann-Mayer C; Talluri K; Cleton A; Eerdekens M; Battisti WP; Palumbo JM
    Int Clin Psychopharmacol; 2007 Sep; 22(5):299-308. PubMed ID: 17690599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.
    Marder SR; Kramer M; Ford L; Eerdekens E; Lim P; Eerdekens M; Lowy A
    Biol Psychiatry; 2007 Dec; 62(12):1363-70. PubMed ID: 17601495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia.
    Berwaerts J; Cleton A; Rossenu S; Talluri K; Remmerie B; Janssens L; Boom S; Kramer M; Eerdekens M
    J Psychopharmacol; 2010 Jul; 24(7):1011-8. PubMed ID: 19825908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial.
    Kim SW; Chung YC; Lee YH; Lee JH; Kim SY; Bae KY; Kim JM; Shin IS; Yoon JS
    Int Clin Psychopharmacol; 2012 Sep; 27(5):267-74. PubMed ID: 22809972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents.
    Singh J; Robb A; Vijapurkar U; Nuamah I; Hough D
    Biol Psychiatry; 2011 Dec; 70(12):1179-87. PubMed ID: 21831359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.
    Emsley R; Berwaerts J; Eerdekens M; Kramer M; Lane R; Lim P; Hough D; Palumbo J
    Int Clin Psychopharmacol; 2008 Nov; 23(6):343-56. PubMed ID: 18854723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label study.
    Schmauss M; Jukić V; Siracusano A; Bidzan L; Badescu GM; Maciulis V; Lahaye M; Hoeben D; Tessier C; Schreiner A
    Curr Med Res Opin; 2012 Aug; 28(8):1395-404. PubMed ID: 22746355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
    Kramer M; Simpson G; Maciulis V; Kushner S; Vijapurkar U; Lim P; Eerdekens M
    J Clin Psychopharmacol; 2007 Feb; 27(1):6-14. PubMed ID: 17224706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study.
    Gattaz WF; Campos JA; Lacerda AL; Henna E; Ruschel SI; Bressan RA; de Oliveira IR; Rocha FL; Grabowski HM; Sacomani E; Louzã MR; Quevedo J; Elkis H; Zorzetto Filho D; Périco Cde A; Lawson FL; Appolinário JC
    Curr Med Res Opin; 2014 Apr; 30(4):695-709. PubMed ID: 24289141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials.
    Janicak PG; Wu JH; Mao L
    Curr Med Res Opin; 2008 Jun; 24(6):1807-15. PubMed ID: 18559166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paliperidone extended-release for the treatment of schizophrenia.
    Marino J; Caballero J
    Pharmacotherapy; 2008 Oct; 28(10):1283-98. PubMed ID: 18823223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers.
    Canuso CM; Schooler N; Carothers J; Turkoz I; Kosik-Gonzalez C; Bossie CA; Walling D; Lindenmayer JP
    J Clin Psychopharmacol; 2010 Oct; 30(5):487-95. PubMed ID: 20814330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.